Quality by Design for Analytical Methods: Implications for Method Validation and Transfer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quality by Design for Analytical Methods: Implications for Method Validation and Transfer
The authors describe how traditional approaches to analytical method and validation may benefit from alignment with quality-by-design concepts.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 74-79

References

1. P. Nethercote, et al., "QbD for Better Method Validation and Transfer," Pharmamanuf. online, http://www.pharmamanufacturing.com/articles/2010/060.html, accessed June 10, 2012.

2. FDA, Pharmaceutical cGMPs for the 21st Century—A Risk-Based Approach (Rockville, MD, 2004).

3. FDA, Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Jan. 2011).

4. M. Nasr, presentation at the AAPS Workshop (North Bethesda, MD, Oct. 5, 2005).

5. ICH, Q2(R1), Validation of Analytical Procedures: Text and Methodology, Step 4 version (2005).

6. P. Borman, et al., Pharm. Tech., 31 (10), 142–152 (2007).

7. USP General Chapter <1058>, "Analytical Instrument Qualification."

8. J. Ermer and J.S. Landy, "Validation of analytical procedures," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan, Eds. (Dekker, New York, 2nd ed., 2002), pp. 507–528.

9. ICH, Q8, Pharmaceutical Development (2009).

10. M. Schweitzer, et al., Pharm. Tech., 34(2), 52–59 (2010).

11. P.J. Borman, et al., Anal. Chim. Acta., 703(2), 101–113 (2011).

12. J. Ermer, et al., J. Pharm. Biomed. Anal., 38(4) 653–663 (2005).

13. USP General Chapter <1010>, "Analytical Data Interpretation & Treatment."

14. ICH, Q9, Quality Risk Management (2005).

15. ICH, Q10, Pharmaceutical Quality System (2008).

16. E. Ciurczak, "ICH Guidances (Already) Show Their Age," http://www.pharmamanufacturing.com/articles/2008/158.html, accessed June 10, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here